U.S. Personal Products Stock News

NYSE:OC
NYSE:OCBuilding

Is It Time To Reassess Owens Corning (OC) After Mixed Returns And Sector Headlines

If you are wondering whether Owens Corning stock offers good value at its current price, it is important to understand what the recent share performance and fundamentals are really saying about the business. The stock last closed at US$124.24, with returns of 7.0% over 7 days, 0.2% over 30 days, 8.8% year to date, a decline of 5.9% over 1 year, and gains of 21.0% over 3 years and 29.6% over 5 years. Taken together, this gives a mixed picture of recent momentum and longer term results. Recent...
NasdaqGS:HAPN
NasdaqGS:HAPNConsumer Finance

LendingClub Rebrands To Happen Bank While Shares Trade Below Targets

LendingClub, traded as NYSE:LC, plans to change its name to Happen Bank this summer. The rebrand is intended to better reflect the company’s identity as a digital bank. The move highlights non earnings news that could influence how customers and investors view the business. LendingClub built its business connecting borrowers and investors online, and now operates as a digital bank offering a broader mix of financial services. The decision to rebrand as Happen Bank points to a tighter focus...
NYSE:CRM
NYSE:CRMSoftware

Salesforce (CRM) Net Margin Improvement Tests Long Term Bullish Narratives

Salesforce (CRM) opened fiscal Q1 2027 with revenue of US$11.1 billion and basic EPS of US$2.43, while over the last 12 months revenue has reached US$42.8 billion and basic EPS stands at US$8.65. The company has seen revenue move from US$9.8 billion and EPS of US$1.61 in Q1 2026 to US$11.1 billion and EPS of US$2.43 in Q1 2027, which may lead investors to focus on how much of that top line is dropping through to profit and what the margin profile suggests about the quality of the growth. See...
NYSE:LEVI
NYSE:LEVILuxury

Is It Too Late To Consider Levi Strauss (LEVI) After Its Strong 3 Year Run?

If you are wondering whether Levi Strauss stock still offers value after its recent run, or if you might be late to the party, this article explains what the current price appears to reflect. The stock last closed at US$23.72, with returns of 9.1% over 7 days, 6.4% over 30 days, 13.9% year to date, 37.2% over 1 year and 98.0% over 3 years, compared with 2.2% over 5 years. Recent coverage has focused on Levi Strauss as a global consumer brand and on how investors are reassessing established...
NYSE:FE
NYSE:FEElectric Utilities

FirstEnergy Ohio Rate Plan Puts Grid Spending And Earnings Outlook In Focus

FirstEnergy's Ohio utilities have submitted a three year rate plan to state regulators that outlines major grid upgrades and expanded customer assistance programs. The filing details substantial planned investment in the electrical grid along with proposals for gradual distribution rate changes for Ohio customers. The plan will go through a regulatory review and public comment process that could influence the final structure of customer rates and assistance offerings. For investors watching...
NYSE:WEC
NYSE:WECIntegrated Utilities

Is WEC Energy Group (WEC) Fairly Priced After Recent Steady Share Performance?

Some investors may be wondering if WEC Energy Group stock at around US$111.67 is offering fair value right now, or if the price is getting ahead of itself. Over the very short term the stock is relatively flat, declining 0.4% over the last week and 3.5% over the last month, while the year to date return sits at 4.9% and the 1 year return at 8.9%, with 3 and 5 year returns of 44.3% and 40.9% respectively. Recent coverage of WEC Energy Group has focused on its position in the regulated...
NYSE:G
NYSE:GProfessional Services

Genpact’s Top Tier GCC Ranking Highlights AI Led Transformation Potential

Genpact (NYSE:G) has been placed in the highest tier by HFS Research for its work in orchestrating and transforming Global Capability Centers. The recognition centers on Genpact's use of AI and platform-led services to support these centers. The ranking underscores the company's role in helping enterprises manage complex operational requirements through Global Capability Centers. For you as an investor, this recognition sits at the intersection of business process management, AI and global...
NYSE:ATHM
NYSE:ATHMInteractive Media and Services

Autohome (NYSE:ATHM) Q1 Net Income Collapse Tests Bullish Margin Narratives

Q1 2026 earnings snapshot sets the stage for Autohome (NYSE:ATHM) Autohome (NYSE:ATHM) opened 2026 with Q1 revenue of C¥1,048.4 million and basic EPS of C¥0.38, alongside net income of C¥44.3 million, putting fresh numbers behind a stock currently trading at $17.30. Over the last few quarters, revenue has moved from C¥1,783.4 million in Q4 2024 to C¥1,453.8 million in Q1 2025 and then to C¥1,048.4 million in Q1 2026, while quarterly basic EPS has shifted from C¥2.51 to C¥2.86 and then to...
NYSE:SQM
NYSE:SQMChemicals

Is It Too Late To Consider Sociedad Química y Minera de Chile (NYSE:SQM) After 169% Surge?

Wondering if Sociedad Química y Minera de Chile at around US$84.05 is still offering value after a strong run, or if you are arriving late to the story. The stock has returned 6.0% over the past week, is down 6.0% over the past month, but is up 20.5% year to date and 169.1% over the last year, which can change how the market is thinking about its risk and reward profile. Recent coverage has focused on Sociedad Química y Minera de Chile as a key player in materials and lithium related themes,...
NYSE:A
NYSE:ALife Sciences

Agilent Technologies (A) Margin Gains Reinforce Bullish Recurring Revenue Narrative After Q2 2026 Results

Agilent Technologies (A) has just reported Q2 2026 results with revenue of US$1,835 million and basic EPS of US$1.20, alongside trailing twelve month revenue of US$7.2 billion and EPS of US$5.00 that sit against a one year earnings growth figure of 21.3%. Over recent quarters, revenue has ranged between US$1,668 million and US$1,861 million while quarterly EPS has moved between roughly US$0.75 and US$1.53, with net profit margin across the last year at 19.6% compared to 17.6% a year earlier...
NasdaqCM:MNTS
NasdaqCM:MNTSAerospace & Defense

A Look At Momentus (MNTS) Valuation After New US$25m Private Placement And Recent Share Price Surge

Momentus (MNTS) has drawn fresh attention after entering securities purchase agreements with existing institutional investors for a private placement of 2,942,000 shares. The transaction is expected to raise about US$25,000,000 in gross proceeds. See our latest analysis for Momentus. The private placement and recent shelf registrations have arrived after a sharp swing in sentiment, with the 30 day share price return of 278.91% and year to date share price return of 237.98% contrasting with a...
NYSE:FPS
NYSE:FPSElectrical

Is It Too Late To Consider Forgent Power Solutions (FPS) After A 64% Year To Date Jump?

Wondering if Forgent Power Solutions at around US$47.56 is offering value or stretching expectations? This article walks through what the current price might be telling you. The stock has eased about 2% over the past week, but is still up 28.9% over the past month and 64.0% year to date, which can change how you think about both upside and risk. Recent coverage has focused on Forgent Power Solutions as investors look more closely at power and grid related companies, with attention on how its...
NasdaqGS:FIZZ
NasdaqGS:FIZZBeverage

Assessing National Beverage (FIZZ) Valuation After Recent Share Price Momentum

Why National Beverage stock is drawing attention National Beverage (FIZZ) is back on investors’ radar after a recent share price move, with returns over the past month and past 3 months prompting closer scrutiny of its fundamentals and valuation. See our latest analysis for National Beverage. At a recent share price of US$37.24, the stock has a 1 month share price return of 7.91% and a year to date share price return of 17.62%, yet the 1 year total shareholder return is down 16.95%. This...
NYSE:VMC
NYSE:VMCBasic Materials

Is Vulcan Materials (VMC) Share Price Outrunning Its Cash Flow And Earnings Outlook

Wondering if Vulcan Materials at a recent US$276.75 close is priced appropriately for its future or offering limited value? This article walks through what the numbers actually say about the stock. Recent returns have been mixed, with the stock up 5.6% over the past week, down 5.0% over the past month, down 5.4% year to date, and up 5.1% over the past year, which can signal changing views on both opportunity and risk. Recent news flow around Vulcan Materials has centered on ongoing interest...
NasdaqCM:GSM
NasdaqCM:GSMMetals and Mining

Exploring Undervalued Small Caps With Insider Action In May 2026

The United States market has shown robust performance recently, climbing 1.8% in the last seven days and rising 28% over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, identifying small-cap stocks that are potentially undervalued and experiencing insider action can present unique opportunities for investors seeking to capitalize on growth prospects within emerging companies.
NasdaqGM:EYPT
NasdaqGM:EYPTPharmaceuticals

Can EyePoint (EYPT) Turn DURAVYU’s Six‑Month Dosing Goal Into Lasting Competitive Advantage?

EyePoint Pharmaceuticals recently presented at the Stifel 2026 Virtual Ophthalmology Forum and reiterated that top-line Phase 3 data for its wet age-related macular degeneration (AMD) therapy DURAVYU are expected to begin reading out in August, with a second pivotal trial to follow about two months later. Management highlighted 2026 as potentially transformative, emphasizing ambitions for DURAVYU to match a leading therapy on vision outcomes while maintaining safety and reducing treatment...
NasdaqGM:LNTH
NasdaqGM:LNTHMedical Equipment

Lantheus ASCO Data To Test Radiopharma Pipeline And Valuation Gap Narrative

Lantheus Holdings (NasdaqGM:LNTH) plans to present new clinical data for LNTH-2403, an LRRC15-targeted radiopharmaceutical, at the 2026 ASCO Annual Meeting. The company will also share real-world data on piflufolastat F 18 imaging use in early-stage prostate cancer at the same conference. These updates provide fresh detail on both Lantheus's osteosarcoma pipeline and the adoption of its approved prostate cancer imaging agent. Lantheus focuses on radiopharmaceuticals and imaging agents used...